SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1643557
Comparative Efficacy and Safety of Xuebijing Injection as Adjuvant Therapy in Sepsis-Associated Acute Kidney Injury: A Systematic Review and Meta-Analysis
Provisionally accepted- 1Jiangxi University of Traditional Chinese Medicine, Nanchang, China
- 2Nanchang University, Nanchang, China
- 3Shanghai University of Traditional Chinese Medicine, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Xuebijing injection is a standardized traditional Chinese medicine formulation comprising extracts from safflower, red peony, Chuanxiong, Angelica, and Salvia miltiorrhiza. It is clinically employed for the treatment of sepsis and associated complications. Methods: This systematic review evaluated the efficacy and safety of Xuebijing injection in treating sepsis-associated acute kidney injury (SA-AKI). Six databases were searched up to September 1, 2024, to identify randomized controlled trials (RCTs) comparing Xuebijing injection combined with conventional therapies versus the same conventional therapies alone. Data from individual RCTs were synthesized by meta-analysis, with effect measures expressed as risk ratios (RRs) or mean differences (MDs) and their 95% confidence intervals (CIs). Trial sequential analysis was used to assess the precision of the effect estimates, and the GRADE system was used to evaluate the quality of evidence. Results: Eighteen RCTs involving 1650 patients were included. Meta-analysis demonstrated that, compared with conventional therapies alone, Xuebijing injection combined with conventional therapies significantly reduced 28-day mortality (RR 0.82%, 95% CI 0.69 to 0.98). It also significantly improved renal function (serum creatinine level: MD -17.55 μmol/L, 95% CI: -23.22 to -11.88; blood urea nitrogen level: MD -1.58 mmol/L, 95% CI -1.83 to -1.32; urine volume: MD 5.83 ml, 95% CI: 3.45 to 8.21), inflammatory cytokines (tumor necrosis factor-alpha level: MD -29.20 ng/ml, 95% CI: -39.15 to -19.25; interleukin-6 level: MD -25.80 ng/mL, 95% CI: -35.56 to -16.04; interleukin-10 level: MD -8.02 ng/mL, 95% CI: -13.98 to 2.07), and immune function (percentage of CD3+ T cells: MD 10.30%, 95% CI 7.77% to 12.84%; percentage of CD3+ T cells: MD 9.57%, 95% CI 3.53% to 15.61%; CD4/CD8 ratio: MD 0.27, 95% CI 0.18 to 0.36). In addition, Xuebijing injection significantly alleviated the severity of SA-AKI as measured by the Acute Physiology and Chronic Health Evaluation II score (MD -3.12, 95% CI: -4.51 to -1.73). Conclusion: Xuebijing injection may help reduce mortality and improve renal function in patients with SA-AKI. However, the certainty of evidence ranged from moderate to very low, underscoring the need for validation through large-scale, double-blind randomized controlled trials.
Keywords: Xuebijing injection, Sepsis, Sepsis-associated acute kidney injury, Traditional Chinese Medicine, Systemic review
Received: 09 Jun 2025; Accepted: 02 Oct 2025.
Copyright: © 2025 Shu, Fan, Yang, Deng, Fang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huan Zhang, zhanghuan4562024@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.